HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Guangzhou Innogen Pharmaceutical / Equity Capital Markets

Guangzhou Innogen Pharmaceutical (2591 HK)

<ul>
<li>Innogen’s business, financial condition, operation results and prospects for the next couple of years are substantially dependent on the successful approval and commercialization of Efsubaglutide Alfa, indicating single product risk. </li>
<li>Due to slower R&amp;D progress and fierce competition brought by first movers and generic drugs, commercialization prospects of Efsubaglutide Alfa is highly uncertain, leading to potential lower-than-expected sales performance.</li>
<li>After Series B+ financing, the post-investment valuation of Innogen is already RMB4.65 billion. However, share price of peers has not done well, which makes us cautious about Innogen's IPO prospects.</li>
</ul>


Innogen’s business, financial condition, operation results and prospects for the next couple of years are substantially dependent on the successful approval and commercialization of Efsubaglutide Alfa, indicating single product risk. 
Due to slower R&amp;D progress and fierce competition brought by first movers and generic drugs, commercialization prospects of Efsubaglutide Alfa is highly uncertain, leading to potential lower-than-expected sales performance.
After Series B+ financing, the post-investment valuation of Innogen is already RMB4.65 billion. However, share price of peers has not done well, which makes us cautious about Innogen's IPO prospects.


Pre-IPO Guangzhou Innogen Pharmaceutical Group- The Good Story of GLP-1 May Not Bring High Valuation

China

Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The company focuses on innovative therapies for diabetes and other metabolic diseases, with its core product being Efsubaglutide Alfa (Diabegone) for type 2 diabetes. It was founded in 2014 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Guangzhou Innogen Pharmaceutical Group- The Good Story of GLP-1 May Not Bring High Valuation

​Innogen's future success hinges on approval of Efsubaglutide Alfa, but uncertainty in commercialization and competition will impact sales...

Xinyao (Criss) Wang

Innogen's future success hinges on approval of Efsubaglutide Alfa, but uncertainty in commercialization and competition will impact sales...